CPI203 --- BET Inhibitor
| Overview | |
| Catalog # | bs-60124c-2-mg-solid |
| Product Name | CPI203 --- BET Inhibitor |
| Specifications | |
| Storage Buffer | Powder |
| Storage Condition | Store in dry, dark place at -20C for 1 year. |
| Target | |
| Product Information | Molecular Weight: 399.9 Formula: C19 H18 Cl N5 O S CAS Number: 1446144-04-2 InChi Key: QECMENZMDBOLDR-AWEZNQCLSA-N InChi: InChI=1S/C19H18ClN5OS/c1-9-10(2)27-19-16(9)17(12-4-6-13(20)7-5-12)22-14(8-15(21)26)18-24-23-11(3)25(18)19/h4-7,14H,8H2,1-3H3,(H2,21,26)/t14-/m0/s1 Smiles: CC1=NN=C2[C@H](CC(N)=O)N=C(C3=C(SC(C)=C3C)N12)C1C=CC(Cl)=CC=1 Purity: 98.0 Solubility: DMSO up to 50 mM Appearance: Solid Power. Shelf Life: 1.0 years |
| Description | CPI203 is a novel potent, selective and cell permeable inhibitor of the bromodomain and extra terminal (BET) family protein BRD4 with an IC50 of ~37 nM (BRD4 α-screen assay). It has an IC50 of ~99 nM in inhibiting Myc expression in MV4-11 cells and an IC50 of ~30 nM in inhibiting IL-6 production in THP-1 cells stimulated with LPS, decreases specific Ser2 phosphorylation of the carboxyl-terminal domain (CTD) of the RNA polymerase II (Pol II) by either endogenous BRD4 or a BRD4 mutant, BRD4 FEE-AAA, that is incapable of binding PTEFb. CPI203 is an analog of JQ-1 but has shown superior bioavailability with oral or intraperitoneal (IP) administration. When mice that were transplanted with primary mouse T-ALL cells, either Fbxw7+/+ or Fbxw7mut/+, were treated with CPI203 at 5 mg/Kg orally twice per day, a significant and rapid reduction in leukemia burden was observed. CPI203 is a useful chemical probe to study the suppression of Myc-dependent cancer development. |
Powered by Bioz